Trails Edge Capital Partners LP Invests $29.63 Million in 4D Molecular Therapeutics, Inc. $FDMT

Trails Edge Capital Partners LP purchased a new position in shares of 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) in the 2nd quarter, according to its most recent Form 13F filing with the SEC. The firm purchased 2,227,917 shares of the company’s stock, valued at approximately $29,631,296. 4D Molecular Therapeutics comprises about 0.0% of Trails Edge Capital Partners LP’s investment portfolio, making the stock its 5th largest holding. Trails Edge Capital Partners LP owned approximately 4.26% of 4D Molecular Therapeutics as of its most recent filing with the SEC.

Other institutional investors have also recently added to or reduced their stakes in the company. Legal & General Group Plc bought a new stake in shares of 4D Molecular Therapeutics during the 2nd quarter valued at $59,000. Wexford Capital LP bought a new stake in shares of 4D Molecular Therapeutics in the third quarter valued at about $41,000. Daiwa Securities Group Inc. increased its position in shares of 4D Molecular Therapeutics by 3,362.0% in the 4th quarter. Daiwa Securities Group Inc. now owns 6,370 shares of the company’s stock valued at $48,000 after acquiring an additional 6,186 shares during the period. Susquehanna Portfolio Strategies LLC acquired a new position in shares of 4D Molecular Therapeutics during the 4th quarter worth approximately $77,000. Finally, Martingale Asset Management L P increased its stake in 4D Molecular Therapeutics by 12.4% during the fourth quarter. Martingale Asset Management L P now owns 11,775 shares of the company’s stock worth $88,000 after acquiring an additional 1,303 shares during the last quarter. 99.27% of the stock is owned by institutional investors and hedge funds.

Insider Activity at 4D Molecular Therapeutics

In related news, insider Scott Bizily sold 9,810 shares of 4D Molecular Therapeutics stock in a transaction dated Tuesday, June 23rd. The stock was sold at an average price of $12.00, for a total value of $117,720.00. Following the completion of the transaction, the insider owned 8,617 shares in the company, valued at approximately $103,404. This trade represents a 53.24% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, insider David Kirn sold 114,746 shares of the stock in a transaction dated Monday, June 22nd. The shares were sold at an average price of $10.47, for a total value of $1,201,390.62. Following the completion of the transaction, the insider directly owned 942,485 shares in the company, valued at $9,867,817.95. This represents a 10.85% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 200,496 shares of company stock worth $2,240,244 in the last ninety days. Insiders own 7.90% of the company’s stock.

Analyst Ratings Changes

FDMT has been the subject of a number of analyst reports. Wall Street Zen cut 4D Molecular Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, May 9th. Chardan Capital upgraded shares of 4D Molecular Therapeutics to a “strong-buy” rating in a research note on Tuesday, July 28th. The Goldman Sachs Group reissued a “buy” rating and set a $32.00 price target on shares of 4D Molecular Therapeutics in a research report on Thursday, August 13th. B. Riley Financial reiterated a “buy” rating on shares of 4D Molecular Therapeutics in a research report on Monday, August 17th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of 4D Molecular Therapeutics in a report on Friday, July 17th. One research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $29.62.

4D Molecular Therapeutics Stock Performance

Shares of FDMT stock traded down $0.24 during trading hours on Friday, hitting $14.67. The stock had a trading volume of 1,096,547 shares, compared to its average volume of 831,050. The stock’s 50 day moving average is $12.11 and its 200 day moving average is $10.30. The company has a debt-to-equity ratio of 0.05, a current ratio of 8.03 and a quick ratio of 8.03. The firm has a market capitalization of $810.37 million, a PE ratio of -5.58 and a beta of 2.73. 4D Molecular Therapeutics, Inc. has a twelve month low of $5.97 and a twelve month high of $16.93.

4D Molecular Therapeutics (NASDAQ:FDMT) last posted its quarterly earnings results on Thursday, August 13th. The company reported ($1.04) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.02) by ($0.02). The company had revenue of $3.78 million during the quarter, compared to the consensus estimate of $3.62 million. 4D Molecular Therapeutics had a negative net margin of 194.74% and a negative return on equity of 41.33%. As a group, research analysts forecast that 4D Molecular Therapeutics, Inc. will post -4.09 earnings per share for the current fiscal year.

4D Molecular Therapeutics Company Profile

4D Molecular Therapeutics, founded in 2015 and headquartered in Emeryville, California, is a clinical-stage biotechnology company focused on the development of targeted gene therapies for rare diseases. The company employs its proprietary Gene Expression AAV (GEA) platform to engineer novel adeno-associated virus (AAV) capsids with enhanced tissue selectivity and transduction efficiency. This platform aims to improve the precision and durability of gene delivery compared to traditional AAV approaches.

4D’s pipeline includes both preclinical and clinical-stage programs across multiple therapeutic areas.